Ž. Rotar

发表

Methotrexate reduces HbA1c concentration but does not produce chronic accumulation of ZMP in patients with rheumatoid or psoriatic arthritis

J. Žibert, S. Pirkmajer, M. Thevis, 2016, Scandinavian journal of rheumatology.

IgA vasculitis in adults: the performance of the EULAR/PRINTO/PRES classification criteria in adults

S. Čučnik, M. Tomšič, A. Hočevar, 2016, Arthritis Research & Therapy.

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

L. Jacobsson, M. Santos, Gareth T. Jones, 2021, Annals of the Rheumatic Diseases.

Roadmap to vasculitis.

Y. Konttinen, P. Bacon, D. Nordström, 2006, Acta reumatologica portuguesa.

Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study

M. Tomšič, A. Hočevar, Ž. Rotar, 2020, BMJ Open.

Dysregulated Expression of Arterial MicroRNAs and Their Target Gene Networks in Temporal Arteries of Treatment-Naïve Patients with Giant Cell Arteritis

S. Čučnik, O. Distler, A. Hočevar, 2021, International journal of molecular sciences.

Risk factors for severe cranial ischaemic complications in giant cell arteritis.

M. Tomšič, A. Hočevar, Ž. Rotar, 2020, Rheumatology.

OP0143 PREDICTORS OF SEVERE CRANIAL ISCHEMIC COMPLICATIONS IN GIANT CELL ARTERITIS

M. Tomšič, Ž. Rotar, R. Ješe, 2019 .

Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis

M. Tomšič, M. Hawlina, A. Hočevar, 2016, Medicine.

A concise review of significantly modified serological biomarkers in giant cell arteritis, as detected by different methods.

G. Thallinger, S. Čučnik, M. Tomšič, 2017, Autoimmunity reviews.

THU0054 Utility of serological parameters in giant cell arteritis for predicting disease complications

G. Thallinger, S. Čučnik, M. Tomšič, 2017 .

Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab.

A. Hočevar, S. Škrgat, Ž. Rotar, 2020, The journal of allergy and clinical immunology. In practice.

Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma.

A. Hočevar, S. Škrgat, Ž. Rotar, 2020, Rheumatology.

COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia

M. Tomšič, A. Hočevar, Ž. Rotar, 2022, Clinical Rheumatology.

The cut-off values for the intima-media complex thickness assessed by colour Doppler sonography in seven cranial and aortic arch arteries.

M. Tomšič, A. Hočevar, Ž. Rotar, 2020, Rheumatology.

Predicting gastrointestinal and renal involvement in adult IgA vasculitis

M. Tomšič, A. Hočevar, Ž. Rotar, 2019, Arthritis Research & Therapy.

Antiphospholipid antibodies in adult IgA vasculitis: observational study

S. Čučnik, M. Tomšič, A. Hočevar, 2018, Clinical Rheumatology.

Early giant cell arteritis: Identifying duration from symptoms to diagnosis, possible therapies and clinically-relevant cell dynamics

S. Čučnik, M. Tomšič, A. Hočevar, 2018 .

Does leflunomide have a role in giant cell arteritis? An open-label study

M. Tomšič, A. Hočevar, Ž. Rotar, 2018, Clinical Rheumatology.

The role of colour doppler ultrasonography of facial and occipital arteries in patients with giant cell arteritis: A prospective study.

M. Tomšič, A. Hočevar, Ž. Rotar, 2017, European journal of radiology.

A Model Predicting Short Term Severity of IgA Vasculitis in Adults

M. Tomšič, A. Hočevar, N. Kejžar, 2017 .

Patient age, gender and extent of purpura may suggest short-term outcomes in adults with IgA vasculitis.

S. Čučnik, M. Tomšič, A. Hočevar, 2015, Rheumatology.

Incidence of IgA vasculitis in the adult Slovenian population

M. Tomšič, A. Hočevar, A. Vizjak, 2014, The British journal of dermatology.

The incidence rate and the early management of rheumatoid arthritis in Slovenia

M. Tomšič, A. Hočevar, K. Perdan-Pirkmajer, 2018, Clinical Rheumatology.

The incidence of giant cell arteritis in Slovenia

M. Tomšič, M. Hawlina, A. Hočevar, 2018, Clinical Rheumatology.

FRI0249 IGAV Score – A Feasible Predictor of IGA Vasculitis Severity

M. Tomšič, S. Praprotnik, A. Hočevar, 2015 .

A comprehensive single-cell atlas of freshly dissociated human synovium in inflammatory arthritis with an optimized dissociation protocol for prospective fresh synovial biopsy collection

Mark D. Robinson, S. Čučnik, O. Distler, 2022, bioRxiv.

Acinar epithelial cell laminin-receptors in labial salivary glands in Sjögren's syndrome.

Y. Konttinen, I. Virtanen, B. Rozman, 2008, Clinical and experimental rheumatology.

Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.

K. Pavelka, D. D. Giuseppe, M. Santos, 2022, Seminars in arthritis and rheumatism.

The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis—A Two-Year Prospective Study

S. Čučnik, P. Žigon, A. Mavri, 2021, Biomedicines.

Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry

M. Tomšič, S. Praprotnik, A. Hočevar, 2015, Clinical Rheumatology.

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.

W. Dixon, M. A. van de Laar, P. V. van Riel, 2015, Rheumatology.

Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements

S. Čučnik, M. Tomšič, S. Praprotnik, 2018, Clinical Rheumatology.

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

B. Leeb, K. Pavelka, M. Santos, 2022, Annals of the Rheumatic Diseases.

Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology

M. D. de Wit, R. Landewé, P. Machado, 2021, RMD Open.

Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.

L. Jacobsson, H. Mann, G. Macfarlane, 2020, Rheumatology.

Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome?

Y. Shoenfeld, R. Cervera, A. Tincani, 2009, Lupus.

AB0334 Methotrexate Reduces Hba1c in Non-Diabetic Patients with Newly Diagnosed Rheumatoid Arthritis or Psoriatic Arthritis

S. Pirkmajer, M. Tomšič, S. Praprotnik, 2014 .

Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals

S. Čučnik, P. Žigon, K. Lakota, 2022, Frontiers in Immunology.

Comment on: Is early-onset primary Sjögren's syndrome a worse prognosis form of the disease?

M. Tomšič, S. Praprotnik, A. Hočevar, 2019, Rheumatology.

Comparison of the different classification criteria sets for primary Sjögren's syndrome

T. Kveder, M. Tomšič, G. Vidmar, 2006, Scandinavian journal of rheumatology.

Concerns about the prevalence of primary Sjögren's syndrome: comment on the article by Theander et al.

M. Tomšič, S. Praprotnik, Ž. Rotar, 2005, Arthritis and rheumatism.

Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes.

D. T. Gray, Janet A. Blood, I. Bruce, 2020, Rheumatology.

After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries

B. Leeb, K. Pavelka, D. Courvoisier, 2022, Annals of the Rheumatic Diseases.

Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration

K. Pavelka, S. Saevarsdottir, H. Canhão, 2018, Scandinavian journal of rheumatology.

Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration

K. Pavelka, M. Santos, H. Canhão, 2017, The Journal of Rheumatology.

Comment on: High-risk pregnancy and the rheumatologist.

M. Tomšič, S. Praprotnik, Ž. Rotar, 2015, Rheumatology.

COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases

S. Čučnik, A. Hočevar, P. Žigon, 2021, Frontiers in Immunology.

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

H. Mann, M. Santos, A. Loft, 2021, Arthritis care & research.

Brief report: first identification of H₄ histamine receptor in healthy salivary glands and in focal sialadenitis in Sjögren's syndrome.

H. Stark, A. Falus, E. Buzás, 2012, Arthritis and rheumatism.

An Optimized Tissue Dissociation Protocol for Single-Cell RNA Sequencing Analysis of Fresh and Cultured Human Skin Biopsies

Mark D. Robinson, Mitchell P. Levesque, O. Distler, 2022, Frontiers in Cell and Developmental Biology.

Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study

M. Tomšič, A. Hočevar, Ž. Rotar, 2022, Frontiers in Medicine.

Clinical contrasts with the American College of Rheumatology/European League Against Rheumatism provisional definitions of remission in rheumatoid arthritis for clinical trials: Comment on the article by Felson et al.

M. Tomšič, S. Praprotnik, Ž. Rotar, 2011, Arthritis and rheumatism.

OP0109 CO-MEDICATION WITH A CONVENTIONAL SYNTHETIC DMARD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH IMPROVED RETENTION OF TNF INHIBITORS: RESULTS FROM THE EUROSPA COLLABORATION

L. Jacobsson, H. Mann, G. Macfarlane, 2020, Annals of the Rheumatic Diseases.

The predictive value of urinary vascular endothelial growth factor (VEGF) on worsening kidney function in proteinuric chronic kidney disease.

J. Osredkar, J. Pajek, J. Lindič, 2017, Clinical nephrology.

Vasculitis as Temporally Associated With COVID-19 Infection or Vaccination: A Single-center Experience

M. Tomšič, A. Hočevar, Z. Simonović, 2021, The Journal of Rheumatology.

IgA vasculitis in adults: few certainties and many uncertainties

M. Tomšič, A. Hočevar, Ž. Rotar, 2019, Annals of the rheumatic diseases.

The Role of Statins on the Outcomes on the Cholesterol Embolism Syndrome with Secondary Vasculitis-A Case Report and Review of the Literature

M. Tomšič, S. Praprotnik, A. Hočevar, 2017 .

The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.

C. Turesson, X. Mariette, K. Pavelka, 2020, Rheumatology.

Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.

L. Jacobsson, H. Mann, K. Pavelka, 2020, Rheumatology.

Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration

H. Mann, J. Gómez-Reino, K. Pavelka, 2019, Annals of the rheumatic diseases.

Utility of serological biomarkers for giant cell arteritis in a large cohort of treatment-naïve patients

G. Thallinger, S. Čučnik, M. Tomšič, 2018, Clinical Rheumatology.

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

G. Macfarlane, K. Pavelka, M. Santos, 2020, RMD open.

The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic

M. Tomšič, S. Praprotnik, Ž. Rotar, 2018, Clinical Rheumatology.

Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia

M. Tomšič, A. Hočevar, S. Gradišnik, 2021, Frontiers in Medicine.

Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice

S. Čučnik, M. Tomšič, A. Hočevar, 2017, Annals of the rheumatic diseases.

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.

K. Pavelka, M. Santos, D. Courvoisier, 2020, Seminars in arthritis and rheumatism.

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis.

L. Jacobsson, H. Mann, M. Santos, 2022, Rheumatology.

A reference single-cell map of freshly dissociated human synovium in inflammatory arthritis with an optimized dissociation protocol for prospective synovial biopsy collection

Mark D. Robinson, S. Čučnik, O. Distler, 2023, bioRxiv.

The incidence of idiopathic inflammatory myopathies in the adult Slovenian population

S. Čučnik, M. Tomšič, A. Hočevar, 2018, Clinical Rheumatology.

Incidence of scleroderma spectrum disorders in Slovenia.

M. Tomšič, Ž. Rotar, A. Sipek Dolničar, 2013, Clinical and experimental rheumatology.

EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology

M. D. de Wit, R. Landewé, P. Machado, 2022, Annals of the Rheumatic Diseases.

The frequency of tuberculosis chemoprophylaxis prior to TNF-α inhibitor treatment, and the incidence tuberculosis infection using a two-step screening algorithm for latent tuberculosis infection: data from the BioRx.si registry

M. Tomšič, Ž. Rotar, 2012, Annals of the Rheumatic Diseases.

Comparison of the performance of the different classification criteria for primary Sjögren’s syndrome: a prospective cohort study

M. Tomšič, G. Vidmar, A. Ambrožič, 2014, Clinical Rheumatology.

One-third of European axial spondyloarthritis patients reach pain"remission" with routine care TNF-inhibitor treatment.

G. Jones, G. Macfarlane, K. Pavelka, 2022, Journal of Rheumatology.

The incidence of spondyloarthritis in Slovenia

M. Tomšič, A. Hočevar, Ž. Rotar, 2019, Medicine.

Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2

S. Čučnik, M. Zdravković, P. Žigon, 2022, International journal of molecular sciences.

Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF-inhibitor: results from 13 European registries.

G. Macfarlane, M. Santos, A. Loft, 2023, Rheumatology.

Short-term outcome of patients with adult IgA vasculitis: a single-center experience

M. Tomšič, A. Hočevar, Ž. Rotar, 2023, Frontiers in medicine.

OA18 Smoking and high BMI are associated with reductions in TNF inhibitor response in psoriatic arthritis: results from 12 European countries

G. Jones, G. Macfarlane, M. Santos, 2023, Rheumatology.

Survivin polymorphism is associated with disease activity in rheumatoid arthritis patients.

S. Čučnik, M. Tomšič, S. Praprotnik, 2016, Pharmacogenomics.

Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis.

M. Tomšič, A. Hočevar, Ž. Rotar, 2018, Rheumatology.

Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

B. Gudbjornsson, T. Love, G. Gröndal, 2023, Arthritis Research & Therapy.

Disturbed Antioxidant Capacity in Patients with Systemic Sclerosis Associates with Lung and Gastrointestinal Symptoms

S. Čučnik, J. Osredkar, B. Burja, 2023, Biomedicines.

SAT0206 Retention of tocilizumab as monotherapy versus tnf inhibitors with conventional synthetic dmards in rheumatoid arthritis patients with inadequate response to tnf inhibitors: a study from the tocerra collaboration

K. Pavelka, C. Gabay, C. Codreanu, 2017 .

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries

K. Pavelka, M. Santos, D. Courvoisier, 2018, RMD Open.

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.

D. D. Giuseppe, B. Gudbjornsson, F. Iannone, 2024, Seminars in Arthritis & Rheumatism.

A concise review of significantly modified serological biomarkers in giant cell arteritis, as detected by different methods.

G. Thallinger, S. Čučnik, J. Feichtinger, 2017, Autoimmunity Reviews.

THU0268 Visual Complications in Giant Cell Arteritis – Beyond Inflammation

M. Tomšič, S. Praprotnik, A. Hočevar, 2015 .

SAT0391 REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE – POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK

L. Jacobsson, H. Mann, K. Pavelka, 2019, Saturday, 15 June 2019.

Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

B. Gudbjornsson, T. Love, F. Iannone, 2024, The Journal of Rheumatology.

Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network

B. Gudbjornsson, F. Iannone, B. Glintborg, 2023, RMD Open.

Enthesitis in a European registry-based cohort of patients with psoriatic arthritis treated with tumour necrosis factor inhibitors: clinical burden, patient-reported outcomes, and treatment response

B. Glintborg, Ž. Rotar, H. Relas, 2024, Scandinavian journal of rheumatology.